SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) saw some unusual options trading on Tuesday. Stock traders acquired 261,202 call options on the stock. This represents an increase of 522% compared to the average volume of 42,008 call options.
Wall Street Analyst Weigh In
SLS has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, October 15th. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SELLAS Life Sciences Group currently has a consensus rating of “Hold” and an average target price of $10.00.
Read Our Latest Analysis on SLS
Institutional Inflows and Outflows
SELLAS Life Sciences Group News Summary
Investors following SLS have been watching these news items:
- Positive Sentiment: SELLAS reported that its Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary endpoint in a specific group of patients with acute myeloid leukemia (AML). GPS was associated with a 41% lower risk of death and median overall survival of 24 months, versus 14.7 months with best available treatment (hazard ratio 0.59; p=0.035). The positive efficacy result is the main catalyst behind the stock’s initial surge. SELLAS REGAL trial results
- Neutral Sentiment: Trading activity was unusually intense, including temporary volatility-related trading pauses and a large increase in call-option volume, reflecting heightened investor interest as well as elevated volatility.
- Negative Sentiment: SELLAS announced a proposed $150 million underwritten public offering. Issuing shares could dilute existing shareholders and added selling pressure after the trial-driven rally. Proposed public offering
SELLAS Life Sciences Group Trading Down 6.3%
Shares of SLS opened at $17.95 on Thursday. The firm has a market capitalization of $3.66 billion, a P/E ratio of -89.75 and a beta of 2.73. The firm has a fifty day moving average price of $11.09 and a 200-day moving average price of $8.94. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $24.89.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05).
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Featured Stories
- Five stocks we like better than SELLAS Life Sciences Group
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
